European Pharma Contract Development and Manufacturing Market Set for $68.12 Billion Valuation by 2030
Meticulous Research®, a leading global market
research company, published a research report titled, 'Europe
Pharmaceutical Contract Development and Manufacturing Market by
Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)],
Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma,
Generic] - Forecast to 2030.’
Download Free Sample Report@ https://www.meticulousresearch.com/download-sample-report/cp_id=5592?utm_
&utm_medium=social&utm_campaign=product&utm_content=14-11-2024
According to
the latest publication by Meticulous Research®, the Europe pharmaceutical
contract development and manufacturing (CDMO) market is projected to reach
$68.12 billion by 2030, growing at a CAGR of 7.4% between 2024 and 2030. This
growth is driven by several factors, including the increasing prevalence of
chronic diseases, rising health awareness, a growing elderly population, higher
pharmaceutical R&D spending, cost-effective manufacturing solutions,
increased government support for drug development, improvements in healthcare
infrastructure, and rising healthcare expenditures.
However, the
market faces challenges such as a shortage of skilled professionals.
Nonetheless, opportunities for growth exist, particularly in the high demand
for personalized medicine, cell and gene therapies, as well as advancements in
high potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug
Conjugates (ADC) within European countries.
Key Players
Prominent
companies in the European pharmaceutical CDMO market include AbbVie Inc.
(U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma
International GmbH (Germany), Catalent, Inc. (U.S.), Lonza Group Ltd.
(Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), Boehringer Ingelheim
(Germany), Eurofins Scientific (France), Curia Global, Inc. (U.S.), Thermo
Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany), Cambrex
Corporation (U.S.), Siegfried Holdings AG (Switzerland), Fabbrica Italiana
Sintetici S.p.A. (Italy), and Corden Pharma GmbH (Germany).
Market
Segmentation and Outlook
The Europe
pharmaceutical CDMO market is segmented by service type, end user, and
geography. By service type, the market includes pharmaceutical manufacturing
services (Active Pharmaceutical Ingredient (API) manufacturing and Finished
Dosage Forms (FDF) manufacturing), drug development services, and biologics
manufacturing services. In 2024, pharmaceutical manufacturing services are
expected to dominate, driven by the need for cost-efficient manufacturing,
high-quality bulk production, and the growing demand for generic drugs.
In terms of
end users, generic pharmaceutical companies are expected to see the highest
growth rate, as competition in the generic market intensifies and companies
increasingly turn to contract manufacturing to adopt cutting-edge technologies
and reduce costs.
Geographic
Overview
The report
covers key European markets such as Germany, the U.K., France, Italy, Spain,
Switzerland, the Netherlands, Denmark, and the Rest of Europe. Germany is
anticipated to hold the largest market share in 2024, given its status as a
leading exporter of medicinal products and a top pharmaceutical producer
globally. The country’s focus on personalized medicine and biopharmaceuticals
is expected to drive demand for CDMO services.
In response to
rising demand, CDMOs in Germany are expanding their facilities. For instance,
in July 2021, Richter-Helm Biologics GmbH & Co. KG opened a new production
facility in Bovenau, Germany, significantly increasing its biopharmaceutical
manufacturing capacity.
Conclusion
The Europe
pharmaceutical CDMO market is poised for substantial growth over the coming
years. While challenges like skill shortages and competition exist,
opportunities driven by innovations in personalized medicine, biologics, and
increased demand for cost-effective manufacturing solutions present a promising
future for the sector. Strategic partnerships and technological advancements
will be crucial for companies aiming to establish a strong market presence.
About Meticulous
Research®:
We are a
trusted research partner for leading businesses worldwide, empowering Fortune
500 organizations and emerging enterprises with actionable market intelligence
tailored to drive revenue transformation and strategic growth. Our insights
reveal forward-looking revenue opportunities, providing our clients with a
competitive edge through a diverse suite of research solutions—syndicated
reports, custom research, and direct analyst engagement.
Each year,
we conduct over 300 syndicated studies and manage 60+ consulting engagements
across eight key industry sectors and 20+ geographic markets. With a focus on
solving the complex challenges facing global business leaders, our research
enables informed decision-making that propels sustainable growth and
operational excellence. We are dedicated to delivering high-impact solutions
that transform business performance and fuel innovation in the competitive
global marketplace.
Contact
Us:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
Email- sales@meticulousresearch.com
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Visit Our Website: https://www.meticulousresearch.com/
For Latest Update Follow Us:
LinkedIn- https://www.linkedin.com/company/meticulous-research
Meticulous Blog | Top Market Research Reports Blog - https://meticulousblog.org/
Comments
Post a Comment